[Re-recognition of methotrexate monotherapy in rheumatoid arthritis].

With the in-depth research on treatment drugs of rheumatoid arthritis (RA), a variety of disease modifying anti-rheumatic drugs (DMARDs) have been approved for the treatment of RA. By now methotrexate (MTX) is still the anchor drug for RA treatment. The 2019 European League Against Rheumatism (EULAR) and 2021 American College of Rheumatology (ACR) recommendations for RA management both point out that for newly diagnosed RA patients, MTX monotherapy should be used as the first choice, which shows the importance of MTX monotherapy in DMARDs naïve RA. This paper mainly reviews the relevant researches on MTX in the treatment of RA in recent years, especially the relevant literature on the use of MTX monotherapy in initial treatment of RA. We summarize the development history, efficacy, treatment and adverse reactions of MTX to recognize the importance of MTX in the treatment of RA and the feasibility of MTX monotherapy.随着对类风湿关节炎（RA）治疗药物研究的深入，多种改善病情抗风湿药（DMARDs）被批准用于治疗RA，但甲氨蝶呤（MTX）仍是RA治疗的基础药物。2019年欧洲抗风湿病联盟（EULAR）及2021年美国风湿病学会（ACR）关于RA的治疗推荐意见均指出对于初治RA患者，MTX单药治疗仍应作为首选方案，由此可见MTX单药治疗的重要性。本文主要回顾了近年来关于MTX治疗RA的相关研究，尤其是单药方案用于RA初始治疗的相关文献，对MTX治疗RA的发展历程、疗效、治疗方式、不良反应等进行总结，更全面地认识MTX在RA治疗中的重要性及MTX单药治疗的可行性。.